Xilis’ rapid and scalable patient-derived MicroOrganoSphereTM (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development.
Compared to conventional patient-derived models, MOS provides faster, higher-throughput, and greater cost savings, as well as more predictive and accurate results. MOS can be used in large-scale pharmacogenomic studies that are representative of the breadth of human genetic diversity during pre-clinical development. We believe the technology not only has the potential to make research more cost efficient, but also significantly more effective.
With ultra high-throughput screening and custom assay capabilities, drug developers can use MOS from preclinical studies to proof of concept clinical trials. We believe this approach provides the highest probability of success for our collaboration partners and is the right way to create value for them, for Xilis, and most importantly, for patients.
Choosing the Right Patient Populations
Personalized medicines in immuno-oncology and infectious disease are crucial to ensure patients get the most effective treatment regimen. The MOS technology enables drug targeting for specific populations. Following tissue biopsy and generation of patient-derived MOS, researchers and clinicians can predict which patient populations will benefit most from a specific drug. By incorporating this step, Xilis’ MOS technology can help reduce time and costs at all stages of the drug development process, from lead generation through clinical studies.
To learn more about MOS and Precision Oncology, click here
- Head & neck
- Nasal epithelium
- Olfactory bulb
Validation in Solid Tumors and Healthy Tissues
MOS has been established and validated in both cancer and healthy tissues. With a high establishment rate, Xilis’ technology allows for the handling of complex samples that can generate usable models from multiple primary tissue types. This helps drug developers determine both safety and efficacy of a specific drug in diseased or normal conditions. Xilis’ MOS ATLAS -- a compilation of MOS from a wide breadth of organs and patients -- can be used for robust, rapid and efficient pharmacogenetic studies at scale.
MOS enables researchers to develop assays that test functionality. Shown in the figure are hepatocytes derived from a patient’s liver. The hepatocyte MOS remains functional after establishment as demonstrated by internalization of LDL from the media.
Immuno-oncology Drug Development
Xilis’ platform provides drug developers an innovative technique to evaluate immuno-oncology therapeutic candidates. Since each MOS captures the full microenvironment and cellular heterogeneity of the patient’s tumor, our high-throughput platform can be used to investigate how single agents or combination therapies induce the immune system response and its ability to kill tumor cells. For example, lung cancer MOS are grown and established. T-cells are then added and activated. The T-cells attack the MOS. Green dye (Caspase3/7) is used to label dying cells, demonstrating the cytotoxic effect T-cells have on MOS.
The graph on the right quantifies the fluorescence intensity, making it a quantitative assay.
Pharmaceutical companies can use Xilis’ platform to investigate immunotherapeutic candidates (e.g. checkpoint inhibitors, CAR-T, TILs) as our MOS captures the full tumor microenvironment. By using our technology, drug developers can increase clinical trial success rates by ensuring drugs are safe and effective, and to target patients most likely to respond to treatment.